West Pharma
The Daikyo Crystal Zenith polymer, with its glass-like transparency and superior packaging attributes, make it the ideal choice for packaging sensitive biologics and other drugs, including oncology drug products, products that react with glass and freeze-dried or protein-based products.
West has announced the first peer-reviewed data demonstrating the benefits of Daikyo Crystal Zenith vials for the synthesis of radiopharmaceutical products. The study, conducted by researchers from Massachusetts General Hospital’s Division of Nuclear Medicine and Molecular Imaging, compared the effectiveness of container closure systems made from the Daikyo Crystal Zenith cyclic olefin polymer with glass for peptide-labelled radiopharmaceuticals. The study results appear in the October 2013 issue of Applied Radiation and Isotopes.
Peptide-based radiopharmaceuticals are used for the diagnosis and treatment of cancer and other therapeutic applications. Glass vials have traditionally been used as the container to enable the necessary chemical reaction that attaches radioisotopes to peptides. However, many peptides can easily be adsorbed by the walls of container closure systems, which means that costly radiopharmaceutical product is not fully recoverable after the reaction has occurred.
The study, 'A container closure system that allows for greater recovery of radiolabeled peptide compared to the standard borosilicate glass system', examined how much product adhered to Crystal Zenith vials compared with glass vials during the synthesis of peptide-labelled radiopharmaceuticals. Key findings from the study include the following:
· container closure systems made of Crystal Zenith had less product adherence to vials compared with single-use glass vials
· crystal Zenith vials retained approximately 10% less of the radiopharmaceutical compared with glass vials
· improved recovery of radiopharmaceuticals in Crystal Zenith vials was due in part to a lower adherence of the peptide.
“Over the past several years, we have seen tremendous interest in Crystal Zenith vials and syringes for drug packaging due to its ability to overcome issues of breakage, delamination and particulates associated with glass container closure systems,” said Vinod Vilivalam, Ph.D., Senior Director, Global Technical Marketing Daikyo-West Products, West. “This study is an important addition to the growing body of evidence showing Crystal Zenith container closure systems are an effective alternative to glass, especially in emerging areas of cell therapy and radiopharmaceuticals.”
West Pharmaceutical Services, Inc., +1 610 594 2900, west.pharmaceutical.services@westpharma.com, www.westpharma.com.